Dr. Suheda Erener is currently investigating whether micro-RNAs – a family of single-stranded molecules which are key regulators of gene expression and beta cell function – can predict the development of T1D.
Sernova Corp., a regenerative medicine company based in London, ON., has shown in its JDRF-funded clinical trial that its cell replacement therapy, Cell PouchTM, can restore insulin production among people living with T1D.
This month, twenty years ago, a pioneering clinical trial in Alberta marked a major advancement in islet transplantation for the treatment of type 1 diabetes (T1D).
